INTERVIEW: Glenmark's Buschle on how it hopes to 'BEAT' cancer
This article was originally published in Scrip
Executive Summary
Michael Buschle, Glenmark's chief scientific officer and president (biologics), clearly values the Indian firm's "entrepreneurial culture" and "flexibility", even if it means doing cutting edge R&D with relatively smaller budgets than Big Pharma enjoys.
You may also be interested in...
Ex-Sanofi Exec Stoeckli Primes Glenmark’s Cancer Therapy Ambitions
Glenmark’s president and chief scientific officer, Dr Kurt Stoeckli, believes that some big pharma companies may have missed the opportunity to embark on immunotherapy cancer treatment R&D “at the right time” and tells Scrip that there is room for the Indian firm to provide competitive assets in the space. Stoeckli, an ex-Sanofi senior executive, also outlines why the upside potential of Glenmark’s BEAT antibody technology platform is “remarkable”.
Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena
Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.
Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena
Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.